Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SYGNIS AG Successfully Completes Rights Offering and Private Placement

Published: Monday, October 28, 2013
Last Updated: Monday, October 28, 2013
Bookmark and Share
Company plans to use EUR 2.7 million to finance its operating business and further growth.

SYGNIS AG has announced that the Company has successfully completed its rights offering. The subscription price was € 2.65 per share.

New shares that were not subscribed in the course of the rights offering by existing shareholders were offered to selected German and international institutional investors in a private placement at a purchase price equivalent to the subscription price. In the transaction 1,019,309 new shares against cash were subscribed.

The Management Board, with the approval of the Supervisory Board, has resolved to increase the Company’s share capital from € 9,364,258.00 to € 10,383,567.00 by issuing 1,019,309 new shares.

The offering utilizes existing authorized capital created by resolution at the Annual General Meeting on August 28, 2013. The new shares carry full dividend rights as of January 1, 2013.

“We welcome our new shareholders and are very thankful for their trust in the new business direction of SYGNIS,” stated Pilar de la Huerta, CEO and CFO of SYGNIS AG. “SYGNIS is a key player in the fast growing market of DNA amplification and sequencing. With the first commercial agreement around SYGNIS’ core technology QualiPhi® with QIAGEN, the world leading provider of sample and assay technologies and a full pipeline with potential blockbuster products for next generation sequencing applications, SYGNIS is best positioned to benefit from the high growth rates we are seeing in gene-based personalized healthcare, molecular diagnostics and epigenetics. The transaction is in our view in the best interest of the Company and its shareholders as it provides the Company with the financial flexibility needed to further execute on its business plans and closes the gap to break-even expected in 2014.”

SYGNIS plans to use the gross proceeds of EUR 2.7 million to finance its operating business and further growth.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SYGNIS AG Signs Non-Exclusive Distribution Agreement with GeneWorks Pty Ltd
Agreement covers the entire SYGNIS portfolio of powerful tools for next generation sequencing and single cell analysis applications.
Tuesday, August 25, 2015
SYGNIS AG Signs Distribution Agreement with Chinese Nanodigmbio Co. Ltd.
Distribution agreement covers the entire SYGNIS portfolio of powerful tools addressing key challenges in NGS and single cell analysis.
Saturday, August 22, 2015
SYGNIS Signs Initial Distribution Agreement with FUNAKOSHI
TruePrime™ family for whole genome amplification without the need of synthetic random primers on stock and ready for distribution in Japan.
Thursday, March 05, 2015
SYGNIS Signs Initial Non-Exclusive Distribution Agreement with BioCat
TruePrime™ Single Cell WGA kit to be launched early 2015.
Tuesday, December 30, 2014
SYGNIS Announces Double Switch Technology Patent Deal with SYSTASY
Company reiterates strategic deals with leading industry partners.
Tuesday, May 13, 2014
SYGNIS Reports Financial Results for a Successful Fiscal Year 2013
First products launched based on QualiPhi® now renamed SensiPhi® in early 2014.
Wednesday, April 02, 2014
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!